



# COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses




Muhammad Adnan Shereen<sup>b,1</sup>, Suliman Khan<sup>a,1,\*</sup>, Abeer Kazmi<sup>c</sup>, Nadia Bashir<sup>b</sup>, Rabeea Siddique<sup>a</sup>

<sup>a</sup> The Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China

<sup>b</sup> State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, PR China

<sup>c</sup> College of Life Sciences, Wuhan University, Wuhan, PR China

## GRAPHICAL ABSTRACT



## ARTICLE INFO

### Article history:

Received 15 March 2020

Accepted 15 March 2020

Available online 16 March 2020

### Keywords:

Coronaviruses  
COVID-19  
Transmission  
Outbreak  
Spread

## ABSTRACT

The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused global pandemic that led to a dramatic loss of human life worldwide. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.

© 2020 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Coronaviruses belong to the Coronaviridae family in the Nidovirales order. Corona represents crown-like spikes on the outer surface of the virus; thus, it was named as a coronavirus.

Peer review under responsibility of Cairo University.

\* Corresponding author.

E-mail address: [suliman.khan18@mails.ucas.ac.cn](mailto:suliman.khan18@mails.ucas.ac.cn) (S. Khan).

<sup>1</sup> Contributed equally (M.A.S and S.K).

<https://doi.org/10.1016/j.jare.2020.03.005>

2090-1232/© 2020 The Authors. Published by Elsevier B.V. on behalf of Cairo University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Coronaviruses are minute in size (65–125 nm in diameter) and contain a single-stranded RNA as a nucleic material, size ranging from 26 to 32kbs in length (Fig. 1). The subgroups of coronaviruses family are alpha ( $\alpha$ ), beta ( $\beta$ ), gamma ( $\gamma$ ) and delta ( $\delta$ ) coronavirus. The severe acute respiratory syndrome coronavirus (SARS-CoV), H5N1 influenza A, H1N1 2009 and Middle East respiratory syndrome coronavirus (MERS-CoV) cause acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) which leads to pulmonary failure and result in fatality. These viruses were thought to infect only animals until the world witnessed a severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV, 2002 in Guangdong, China [1]. Only a decade later, another pathogenic coronavirus, known as Middle East respiratory syndrome coronavirus (MERS-CoV) caused an endemic in Middle Eastern countries [2].

Recently at the end of 2019, Wuhan an emerging business hub of China experienced an outbreak of a novel coronavirus that killed more than eighteen hundred and infected over seventy thousand individuals within the first fifty days of the epidemic. This virus was reported to be a member of the  $\beta$  group of coronaviruses. The novel virus was named as 2019 novel coronavirus (2019-nCoV) by the Chinese researchers. The International Committee on Taxonomy of Viruses (ICTV) named the virus as SARS-CoV-2 and the disease as COVID-19 [3–5]. In the history, SRAS-CoV (2003) infected 8098 individuals with mortality rate of 9%, across 26 countries in the world, on the other hand, novel corona virus (2019) infected 120,000 individuals with mortality rate of 2.9%, across 109 countries, till date of this writing. It shows that the transmission rate of SARS-CoV-2 is higher than SRAS-CoV and the reason could be genetic recombination event at S protein in the RBD region of SARS-CoV-2 may have enhanced its transmission ability. In this review article, we discuss the transmission of human coronaviruses briefly. We further discuss the associated infectiousness and biological features of SARS and MERS with a special focus on COVID-19.

### Comparative analysis of emergence and spreading of coronaviruses

In 2003, the Chinese population was infected with a virus causing Severe Acute Respiratory Syndrome (SARS) in Guangdong province. The virus was confirmed as a member of the Beta-coronavirus subgroup and was named SARS-CoV [6,7]. The infected patients exhibited pneumonia symptoms with a diffused alveolar injury which lead to acute respiratory distress syndrome (ARDS). SARS initially emerged in Guangdong, China and then spread rapidly around the globe with more than 8000 infected persons

and 776 deaths. A decade later in 2012, a couple of Saudi Arabian nationals were diagnosed to be infected with another coronavirus. The detected virus was confirmed as a member of coronaviruses and named as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The World health organization reported that MERS-coronavirus infected more than 2428 individuals and 838 deaths [8]. MERS-CoV is a member beta-coronavirus subgroup and phylogenetically diverse from other human-CoV. The infection of MERS-CoV initiates from a mild upper respiratory injury while progression leads to severe respiratory disease. Similar to SARS-coronavirus, patients infected with MERS-coronavirus suffer pneumonia, followed by ARDS and renal failure [9].

Recently, by the end of 2019, WHO was informed by the Chinese government about several cases of pneumonia with unfamiliar etiology. Although scientists suspected that Hunan seafood market in Wuhan helped the virus spread, however, it was not where the outbreak first emerged [10]. On 12 January 2020, the National Health Commission of China released further details about the epidemic, suggested viral pneumonia [10]. From the sequence-based analysis of isolates from the patients, the virus was identified as a novel coronavirus. Moreover, the genetic sequence was also provided for the diagnosis of viral infection. Initially, it was suggested that the patients infected with Wuhan coronavirus induced pneumonia in China may have visited the seafood market where live animals were sold or may have used infected animals or birds as a source of food. However, further investigations revealed that some individuals contracted the infection even with no record of visiting the seafood market. These observations indicated a human to the human spreading capability of this virus, which was subsequently reported in more than 100 countries in the world. The human to the human spreading of the virus occurs due to close contact with an infected person, exposed to coughing, sneezing, respiratory droplets or aerosols. These aerosols can penetrate the human body (lungs) via inhalation through the nose or mouth (Fig. 2) [11–14].

### Primary reservoirs and hosts of coronaviruses

The source of origination and transmission are important to be determined in order to develop preventive strategies to contain the infection. In the case of SARS-CoV, the researchers initially focused on raccoon dogs and palm civets as a key reservoir of infection. However, only the samples isolated from the civets at the food market showed positive results for viral RNA detection, suggesting that the civet palm might be secondary hosts [15]. In 2001 the samples were isolated from the healthy persons of Hongkong and the molecular assessment showed 2.5% frequency rate of antibodies against SARS-coronavirus. These indications suggested that SARS-coronavirus may be circulating in humans before causing the outbreak in 2003 [16]. Later on, Rhinolophus bats were also found to have anti-SARS-CoV antibodies suggesting the bats as a source of viral replication [17]. The Middle East respiratory syndrome (MERS) coronavirus first emerged in 2012 in Saudi Arabia [9]. MERS-coronavirus also pertains to beta-coronavirus and having camels as a zoonotic source or primary host [18]. In a recent study, MERS-coronavirus was also detected in Pipistrellus and Perimyotis bats [19], proffering that bats are the key host and transmitting medium of the virus [20,21]. Initially, a group of researchers suggested snakes be the possible host, however, after genomic similarity findings of novel coronavirus with SARS-like bat viruses supported the statement that not snakes but only bats could be the key reservoirs (Table 1) [22,23]. Further analysis of homologous recombination revealed that receptor binding spike glycoprotein of novel coronavirus is developed from a SARS-CoV (CoVZXC21 or CoVZC45) and a yet unknown Beta-CoV [24]. Nonetheless, to





Fig. 1. Structure of respiratory syndrome causing human coronavirus.



**Fig. 2.** The key reservoirs and mode of transmission of coronaviruses (suspected reservoirs of SARS-CoV-2 are red encircled); only  $\alpha$  and  $\beta$  coronaviruses have the ability to infect humans, the consumption of infected animal as a source of food is the major cause of animal to human transmission of the virus and due to close contact with an infected person, the virus is further transmitted to healthy persons. Dotted black arrow shows the possibility of viral transfer from bat whereas the solid black arrow represent the confirmed transfer.

**Table 1**  
Comparative analysis of biological features of SARS-CoV and SARS-CoV-2.

Features	SARS-CoV	SARS-CoV-2	Reference
Emergence date	November 2002	December 2019	[37,79–81]
Area of emergence	Guangdong, China	Wuhan, China	
Date of fully controlled	July 2003	Not controlled yet	
Key hosts	Bat, palm civets and Raccon dogs	Bat	[22,82,83]
Number of countries infected	26	109	[84]
Entry receptor in humans	ACE2 receptor	ACE2 receptor	[22,55,85]
Sign and symptoms	fever, malaise, myalgia, headache, diarrhoea, shivering, cough and shortness of breath	Cough, fever and shortness of breath	[12,23,85]
Disease caused	SARS, ARDS	SARS, COVID-19	[85,86]
Total infected patients	8098	123882	[84]
Total recovered patients	7322	67051	
Total died patients	776 (9.6% mortality rate)	4473 (3.61% mortality rate)	

eradicate the virus, more work is required to be done in the aspects of the identification of the intermediate zoonotic source that caused the transmission of the virus to humans.

### Key features and entry mechanism of human coronaviruses


All coronaviruses contain specific genes in ORF1 downstream regions that encode proteins for viral replication, nucleocapsid and spikes formation [25]. The glycoprotein spikes on the outer surface of coronaviruses are responsible for the attachment and entry of the virus to host cells (Fig. 1). The receptor-binding domain (RBD) is loosely attached among virus, therefore, the virus may infect multiple hosts [26,27]. Other coronaviruses mostly recognize aminopeptidases or carbohydrates as a key receptor for entry to human cells while SARS-CoV and MERS-CoV recognize exopeptidases [2]. The entry mechanism of a coronavirus depends upon cellular proteases which include, human airway trypsin-like protease (HAT), cathepsins and transmembrane protease serine 2 (TMPRSS2) that split the spike protein and establish further penetration changes [28,29]. MERS-coronavirus employs dipeptidyl peptidase 4 (DPP4), while HCoV-NL63 and SARS-coronavirus require angiotensin-converting enzyme 2 (ACE2) as a key receptor [2,26].

SARS-CoV-2 possesses the typical coronavirus structure with spike protein and also expressed other polyproteins, nucleopro-

teins, and membrane proteins, such as RNA polymerase, 3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and accessory proteins [30,31]. The spike protein of SARS-CoV-2 contains a 3-D structure in the RBD region to maintain the van der Waals forces [32]. The 394 glutamine residue in the RBD region of SARS-CoV-2 is recognized by the critical lysine 31 residue on the human ACE2 receptor [33]. The entire mechanism of pathogenicity of SARS-CoV-2, from attachment to replication is well mentioned in Fig. 3.

### Genomic variations in SARS-CoV-2

The genome of the SARS-CoV-2 has been reported over 80% identical to the previous human coronavirus (SARS-like bat CoV) [34]. The Structural proteins are encoded by the four structural genes, including spike (S), envelope (E), membrane (M) and nucleocapsid (N) genes. The *orf1ab* is the largest gene in SARS-CoV-2 which encodes the pp1ab protein and 15 nsps. The *orf1a* gene encodes for pp1a protein which also contains 10 nsps [34–36]. According to the evolutionary tree, SARS-CoV-2 lies close to the group of SARS-coronaviruses [37,38] (Fig. 5). Recent studies have indicated notable variations in SARS-CoV and SARS-CoV-2 such as the absence of 8a protein and fluctuation in the number of amino acids in 8b and 3c protein in SARS-CoV-2 [34] (Fig. 4). It is also reported that Spike glycoprotein of the Wuhan coronavirus



**Fig. 3.** The life cycle of SARS-CoV-2 in host cells; begins its life cycle when S protein binds to the cellular receptor ACE2. After receptor binding, the conformation change in the S protein facilitates viral envelope fusion with the cell membrane through the endosomal pathway. Then SARS-CoV-2 releases RNA into the host cell. Genome RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then cleaved into small products by viral proteinases. The polymerase produces a series of subgenomic mRNAs by discontinuous transcription and finally translated into relevant viral proteins. Viral proteins and genome RNA are subsequently assembled into virions in the ER and Golgi and then transported via vesicles and released out of the cell. ACE2, angiotensin-converting enzyme 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment.

is modified via homologous recombination. The spike glycoprotein of SARS-CoV-2 is the mixture of bat SARS-CoV and a not known Beta-CoV [38]. In a fluorescent study, it was confirmed that the SARS-CoV-2 also uses the same ACE2 (angiotensin-converting enzyme 2) cell receptor and mechanism for the entry to host cell which is previously used by the SARS-CoV [39,40]. The single N501T mutation in SARS-CoV-2's Spike protein may have significantly enhanced its binding affinity for ACE2 [33].

### The major obstacle in research progress


Animal models play a vital role to uncover the mechanisms of viral pathogenicity from the entrance to the transmission and designing therapeutic strategies. Previously, to examine the replication of SARS-CoV, various animal models were used which showed the symptoms of severe infection [43]. In contrast to SARS-CoV, no MERS-CoV pathogenesis was observed in small animals. Mice are not vulnerable to infection by MERS-coronavirus due to the non-compatibility of the DPP4 receptor [44]. As the entire genome of the 2019-novel coronavirus is more than 80% similar to the previous human SARS-like bat CoV, previously used animal models for SARS-CoV can be utilized to study the infectious pathogenicity of SARS-CoV-2. The human ACE2 cell receptor is recognized by both SARS and Novel coronaviruses. Conclusively, TALEN or CRISPR-mediated genetically modified hamsters or other small animals can be utilized for the study of the pathogenicity of novel coronaviruses. SARS-CoV has been reported to replicate and cause severe disease in Rats (F344), where the sequence analysis revealed a mutation at spike glycoprotein [45]. Thus, it could be

another suitable option to develop spike glycoprotein targeting therapeutics against novel coronaviruses. Recently, mice models and clinical isolates were used to develop any therapeutic strategy against SARS-CoV-2 induced COVID-19 [46,47]. In a similar study, artificial intelligence prediction was used to investigate the inhibitory role of the drug against SARS-CoV-2 [48]. SARS-CoV-2 infected patients were also used to conduct randomized clinical trials [46,49,50]. It is now important that the scientists worldwide collaborate the design a suitable model and investigate the *in vivo* mechanisms associated with pathogenesis of SARS-CoV-2.


### Potential therapeutic strategies against COVID-19

Initially, interferons- $\alpha$  nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49,51,52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46,50,52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and *in-vitro* clinical isolates [46,48,50,52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients





**Fig. 4.** Betacoronaviruses genome organization; The Betacoronavirus for human (SARS-CoV-2, SARS-CoV and MERS-CoV) genome comprises of the 5'-untranslated region (5'-UTR), open reading frame (orf) 1a/b (green box) encoding non-structural proteins (nsp) for replication, structural proteins including spike (blue box), envelope (maroon box), membrane (pink box), and nucleocapsid (cyan box) proteins, accessory proteins (light gray boxes) such as orf 3, 6, 7a, 7b, 8 and 9b in the SARS-CoV-2 genome, and the 3'-untranslated region (3'-UTR). The dotted underlined in red are the protein which shows key variation between SARS-CoV-2 and SARS-CoV. The length of nsps and orfs are not drawn in scale.



**Fig. 5.** Phylogenetic tree of coronaviruses (content in red is the latest addition of newly emerged SARS-CoV-2 and WSFMP Wuhan-Hu-1 is used as a reference in the tree); The phylogenetic tree showing the relationship of Wuhan-Hu-1 (denoted as red) to selected coronavirus is based on nucleotide sequences of the complete genome. The viruses are grouped into four genera (prototype shown): Alphacoronavirus (sky blue), Betacoronavirus (pink), Gammacoronavirus (green) and Deltacoronavirus (light blue). Subgroup clusters are labeled as 1a and 1b for the Alphacoronavirus and 2a, 2b, 2c, and 2d for the Betacoronavirus. This tree is based on the published trees of Coronavirinae [3,41] and reconstructed with sequences of the complete RNA- dependent RNA polymerase- coding region of the representative novel coronaviruses (maximum likelihood method using MEGA 7.2 software). severe acute respiratory syndrome coronavirus (SARS- CoV); SARS- related coronavirus (SARSr- CoV); the Middle East respiratory syndrome coronavirus (MERS- CoV); porcine enteric diarrhea virus (PEDV); Wuhan seafood market pneumonia (Wuhan-Hu-1). Bat CoV RaTG13 Showed high sequence identity to SARS-CoV-2 [42].

who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds - with the spike RBD of SARS-CoV-2. This is likely due to the antibody's epitope not overlapping with the divergent ACE2

receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of- COVID-19 infection [55].

## Vaccines for SARS-CoV-2

There is no available vaccine against COVID-19, while previous vaccines or strategies used to develop a vaccine against SARS-CoV can be effective. Recombinant protein from the Urbani (AY278741) strain of SARS-CoV was administered to mice and hamsters, resulted in the production of neutralizing antibodies and protection against SARS-CoV [56,57]. The DNA fragment, inactivated whole virus or live-vectored strain of SARS-CoV (AY278741), significantly reduced the viral infection in various animal models [58–63]. Different other strains of SARS-CoV were also used to produce inactivated or live-vectored vaccines which efficiently reduced the viral load in animal models. These strains include, Tor2 (AY274119) [64,65], Utah (AY714217) [66], FRA (AY310120) [59], HKU-39849 (AY278491) [57,67], BJ01 (AY278488) [68,69], NS1 (AY508724) [70], ZJ01 (AY297028) [70], GD01 (AY278489) [69] and GZ50 (AY304495) [71]. However, there are few vaccines in the pipeline against SARS-CoV-2. The mRNA based vaccine prepared by the US National Institute of Allergy and Infectious Diseases against SARS-CoV-2 is under phase 1 trial [72]. INO-4800-DNA based vaccine will be soon available for human testing [73]. Chinese Centre for Disease Control and Prevention (CDC) working on the development of an inactivated virus vaccine [74,75]. Soon mRNA based vaccine's sample (prepared by Stermirna Therapeutics) will be available [76]. GeoVax-BravoVax is working to develop a Modified Vaccina Ankara (MVA) based vaccine [77]. While Clover Biopharmaceuticals is developing a recombinant 2019-nCoV S protein subunit-trimer based vaccine [78].

Although research teams all over the world are working to investigate the key features, pathogenesis and treatment options, it is deemed necessary to focus on competitive therapeutic options and cross-resistance of other vaccines. For instance, there is a possibility that vaccines for other diseases such as rubella or measles can create cross-resistance for SARS-CoV-2. This statement of cross-resistance is based on the observations that children in china were found less vulnerable to infection as compared to the elder population, while children are being largely vaccinated for measles in China.

## Conclusion and perspective

Scientists are still investigating the emergence and origination of SARS-CoV-2. Moreover, its zoonotic source of transmission to humans has not been confirmed yet, however, sequence-based analysis suggested bats as the key reservoir. DNA recombination was found to be involved at spike glycoprotein which assorted SARS-CoV (CoVZXC21 or CoVZC45) with the RBD of another Beta CoV, thus could be the reason for cross-species transmission and rapid infection. According to phylogenetic trees, SARS-CoV is closer to SARS-like bat CoVs. Until now, no promising clinical treatments or prevention strategies have been developed against human coronaviruses. However, the researchers are working to develop efficient therapeutic strategies to cope with the novel coronaviruses. Various broad-spectrum antivirals previously used against influenza, SARS and MERS coronaviruses have been evaluated either alone or in combinations to treat COVID-19 patients, mice models, and clinical isolates. Remdesivir, Lopinavir, Ritonavir, and Oseltamivir significantly blocked the COVID-19 infection in infected patients. It can be concluded that the homologous recombination event at the S protein of RBD region enhanced the transmission ability of the virus. While the decision of bring back the nationals from infected area by various countries and poor screening of passengers, become the leading cause of spreading virus in others countries.

Most importantly, human coronaviruses targeting vaccines and antiviral drugs should be designed that could be used against the

current as well as future epidemics. There are many companies working for the development of effective SARS-CoV-2 vaccines, such as Moderna Therapeutics, Inovio Pharmaceuticals, Novavax, Vir Biotechnology, Stermirna Therapeutics, Johnson & Johnson, VIDO-InterVac, GeoVax-BravoVax, Clover Biopharmaceuticals, CureVac, and Codagenix. But there is a need for rapid human and animal-based trials as these vaccines still require 3–10 months for commercialization. There must be a complete ban on utilizing wild animals and birds as a source of food. Beside the development of most efficient drug, a strategy to rapidly diagnose SARS-CoV-2 in suspected patient is also required. The signs and symptoms of SARS-CoV-2 induced COVID-19 are a bit similar to influenza and seasonal allergies (pollen allergies). Person suffering from influenza or seasonal allergy may also exhibit temprature which can be detected by thermo-scanners, hence the person will become suspected. Therefore, an accurate and rapid diagnostic kit or meter for detection of SARS-CoV-2 in suspected patients is required, as the PCR based testing is expensive and time consuming. It is appreciable that the Chinese health workers have efficiently controlled the outbreak in china and limited the mortality rate to less than 3% only. The therapeutic strategies used by Chinese healthcare authorities, should also be followed by other countries.

## Acknowledgments

The authors acknowledge the Postdoctoral grant from The Second Affiliated Hospital of Zhengzhou University (for S.K).

## Author contribution

Suliman Khan: Conceptualization, investigation, data curation, writing- original draft preparation, reviewing and editing, and supervision. Muhammad Adnan Shereen: Writing-original draft Abber Kazmi, Nadia Bashir and Rabeea Siddique: writing- original draft.

## Declaration of Competing Interest

The authors of this manuscript declare no conflict of interest.

## References

- [1] Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. *The Lancet* 2003;362(9393):1353–8.
- [2] Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. *Cell Res* 2013;23(8):986.
- [3] Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* 2019;17(3):181–92.
- [4] Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. *Int J Antimicrob Agents* 2020;105924.
- [5] Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization, 2020.
- [6] Peiris J, Guan Y, Yuen K. Severe acute respiratory syndrome. *Nat Med* 2004;10(12):S88–97.
- [7] Pyrc K, Berkhout B, Van Der Hoek L. Identification of new human coronaviruses. *Expert Review of Anti-infective Therapy* 2007;5(2):245–53.
- [8] Rahman A, Sarkar A. Risk factors for fatal middle east respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO Line List, 2013–2018. *Am J Public Health* 2019;109(9):1288–93.
- [9] Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeh AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. *N Engl J Med* 2013;368(26):2487–94.
- [10] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *The Lancet* 2020.
- [11] Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. *N Engl J Med* 2020.

- [12] Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance*. 2020;25(4).
- [13] Parry J. China coronavirus: cases surge as official admits human to human transmission. British Medical Journal Publishing Group; 2020.
- [14] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020.
- [15] Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. *J Virol* 2005;79(18):11892–900.
- [16] Zheng BJ, Guan Y, Wong KH, Zhou J, Wong KL, Young BWY, et al. SARS-related virus predating SARS outbreak, Hong Kong. *Emerg Infect Dis* 2004;10(2):176.
- [17] Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. *Virus Res* 2008;133(1):74–87.
- [18] Paden C, Yusof M, Al Hammadi Z, Queen K, Tao Y, Eltahir Y, et al. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. *Zoonoses Public Health* 2018;65(3):322–33.
- [19] Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. *Emerg Infect Dis* 2013;19(3):456.
- [20] Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. *J Virol* 2012;86(23):12816–25.
- [21] Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, et al. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. *J Virol* 2013;87(15):8638–50.
- [22] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* 2020.
- [23] Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020.
- [24] Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerging Microbes & Infections* 2020;9(1):221–36.
- [25] van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *MBio* 2012;3(6):e00473–e512.
- [26] Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* 2013;495(7440):251–4.
- [27] Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol* 2009;7(6):439–50.
- [28] Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol* 2011;85(9):4122–34.
- [29] Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. *J Virol* 2011;85(24):13363–72.
- [30] Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. *Nature* 2020;1–5.
- [31] Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature [Internet]*. 2020;Feb:3.
- [32] Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Science China Life Sciences* 2020;63(3):457–60.
- [33] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. *J Virol* 2020.
- [34] Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. *Cell Host Microbe* 2020.
- [35] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565–74.
- [36] Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. *J Med Virol* 2020.
- [37] Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. *International Journal of Infectious Diseases*. 2020;91:264–6.
- [38] Li B, Si H-R, Zhu Y, Yang X-L, Anderson DE, Shi Z-L, et al. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing. *mSphere*. 2020;5(1).
- [39] Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. *Viruses* 2020;12(2):135.
- [40] Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci* 2020;1–4.
- [41] Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. *J Virol* 2014;88(19):11297–303.
- [42] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv*; 2020.
- [43] Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. *Cur Opin Virol* 2015;13:123–9.
- [44] Cockrell AS, Peck KM, Yount BL, Agnihothram SS, Scobey T, Curnes NR, et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. *J Virol* 2014;88(9):5195–9.
- [45] Nagata N, Iwata N, Hasegawa H, Fukushima S, Yokoyama M, Harashima A, et al. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. *J Virol* 2007;81(4):1848–57.
- [46] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 2020;11(1):1–14.
- [47] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. *BioScience Trends* 2020.
- [48] Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *The Lancet* 2020.
- [49] Ng CS, Kasumba DM, Fujita T, Luo H. Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death. *Cell Death Differ* 2020:1–20.
- [50] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med* 2020.
- [51] Wang BX, Fish EN. editors. Global virus outbreaks: Interferons as 1st responders. *Seminars in immunology*. Elsevier; 2019.
- [52] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020;1–3.
- [53] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *MBio* 2018;9(2):e00221–e318.
- [54] Derebail VK, Falk RJ. ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. *Mass Medical Soc* 2020.
- [55] Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *bioRxiv*; 2020.
- [56] Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. *Virology* 2005;334(2):160–5.
- [57] Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. *Vaccine* 2007;25(4):729–40.
- [58] Yang Z-y, Kong W-p, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 2004;428(6982):561–4.
- [59] Stadler K, Roberts A, Becker S, Vogel L, Eickmann M, Kolesnikova L, et al. SARS vaccine protective in mice. *Emerg Infect Dis* 2005;11(8):1312.
- [60] Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. *Virology* 2005;340(2):174–82.
- [61] Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc Natl Acad Sci* 2004;101(17):6641–6.
- [62] Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci* 2004;101(26):9804–9.
- [63] Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (*Cercopithecus aethiops*) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. *Lancet* 2004;363(9427):2122–7.
- [64] See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. *J Gen Virol* 2006;87(3):641–50.
- [65] Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against

- severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. *J Virol* 2004;78(22):12672–6.
- [66] Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. *Vaccine*. 2006;24(5):652–61.
- [67] Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. *Int Immunol* 2004;16(10):1423–30.
- [68] Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. *DNA Cell Biol* 2004;23(6):391–4.
- [69] Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, et al. Immunogenicity and protective efficacy of purified inactivated Vero-cell SARS vaccine. *Vaccine* 2006;24(7):1028–34.
- [70] Zhou J, Wang W, Zhong Q, Hou W, Yang Z, Xiao S-Y, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. *Vaccine* 2005;23(24):3202–9.
- [71] Qu D, Zheng B, Yao X, Guan Y, Yuan Z-H, Zhong N-S, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. *Vaccine* 2005;23(7):924–31.
- [72] McKay BLP. Drugmakers rush to develop vaccines against china virus the wall street journal. [cited 2020 28 January]; Available from: <<https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026>>.
- [73] Inovio IP. Inovio selected by cepi to develop vaccine against new coronavirus inovio. [cited 2020 29 January]; Available from: <<http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-NewCoronavirus/default.aspx>>.
- [74] J.-H.Z.W. Lee LZ. Chinese scientists race to develop vaccine as coronavirus death toll jumps: South china morning post. [cited 2020 29 January]; Available from: <<https://www.scmp.com/news/china/society/article/3047676/numbercoronavirus-cases-china-doubles-spread-rate-accelerates>>.
- [75] Cheung E. China coronavirus: Hong kong researchers have already developed vaccine but need time to test it, expert reveals: South china morning post. [cited 2020 29 January]; Available from: <https://www.scmp.com/news/hongkong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have>.
- [76] Xinhua. China fast-tracks novel coronavirus vaccine development xinhua. [cited 2020 29 January]; Available from: [http://www.xinhuanet.com/english/2020-01/28/c\\_138739378.htm](http://www.xinhuanet.com/english/2020-01/28/c_138739378.htm).
- [77] Geo-Vax. Geovax and bravovax (wuhan, china) to collaborate on development of coronavirus vaccine. [cited 2020 3 March]; Available from: <https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine>.
- [78] Clover B. Clover initiates development of recombinant subunit- trimer vaccine for wuhan coronavirus (2019-ncov). [cited 2020 6 March]; Available from: <http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=40>.
- [79] Huang Y. The SARS epidemic and its aftermath in China: a political perspective. *Learning from SARS: Preparing for the next disease outbreak*; 2004. p. 116–36.
- [80] Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. *J Clin Invest* 2003;111(11):1605–9.
- [81] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. *The Lancet* 2020.
- [82] Perlman S. Another decade, another coronavirus. *Mass Medical Soc* 2020.
- [83] Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. *Current Opin Virol* 2011;1(6):624–34.
- [84] Vara V. Coronavirus outbreak: The countries affected. 11 MARCH 2020; Available from: <https://www.pharmaceutical-technology.com/features/coronavirus-outbreak-the-countries-affected/>.
- [85] Shi Y, Yi Y, Li P, Kuang T, Li L, Dong M, et al. Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay. *J Clin Microbiol* 2003;41(12):5781–2.
- [86] Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv*. 2020.

**Muhammad Adnan Shereen** is a PhD researcher at Wuhan University, working on Zika virus and coronavirus in the aspects of pathogenesis, drug screening and molecular mechanisms. He is an author in 8 articles published in journals with impact factor more than 5 including the recently accepted paper in *Nature microbiology*.

**Suliman Khan** has completed his PhD degree from Chinese Academy of Sciences and currently working at second affiliated hospital of Zhengzhou university as postdoctoral scientist. He has published more than 25 articles and 5 on SARS-CoV-2 in well reputed journals including *Clinical microbiology and infection (CMI)* and *Journal of clinical microbiology (ASM-JCM)* as first and corresponding author.

**Abeer Kazmi** is a PhD student at Wuhan University.

**Nadia Bashir** is a PhD student at Wuhan University working on coronaviruses. She is an author in more than 5 papers published or accepted in renowned journals.

**Rabeea Siddique** is a PhD student at Zhengzhou university. She has published more than 10 papers in well reputed journals as first or coauthor.